A Phase 4 interventional study of Adalimumab and Non-steroidal Anti-inflammatory Drugs (NSAIDs) in Axial Spondyloarthritis, sponsored by AbbVie. Terminated. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-07-05.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study comparing a treat-to-target (T2T) intense treatment approach with routine treatment (Standard of Care [SOC]) in reducing disease activity in participants with axial spondyloarthritis (axSpA).
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
This study's enrollment of 22 is below the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Browse Axial Spondyloarthritis studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants initially received treatment with any non-steroidal anti-inflammatory drug (NSAID) at full anti-inflammatory dose for 4 weeks. After 4 weeks, if the Ankylosing Spondylitis Disease Activity Score (ASDAS) was ≥ 2.1 or treatment with NSAID 1 was not tolerated, treatment was changed to a second NSAID at full anti-inflammatory dose for 4 weeks. If ASDAS was ≥ 2.1 after 4 weeks of NSAID 2 or treatment with the chosen NSAID was not tolerated, , participants were switched to receive a combination of NSAID and adalimumab 40 mg every other week for up to 48 weeks.
Biological: Adalimumab
Participants received treatment as prescribed by their physician according to the local standard of care.
Other: Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
Also known as: Humira, ABT-D2E7
ASAS recommended NSAID doses to treat axial spondyloarthritis.
Also known as: Routine practice
Percentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 32
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.
Time frame: Week 32
Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire
The EQ-5D-3L is a health state utility instrument that evaluates preference for health status (utility). The 5 items in the EQ-5D-3L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 3 levels of severity (1: indicating no problem, 2: indicating some/moderate problems, 3: indicating extreme problems). A single preference-weighted health utility index score was calculated by applying country-specific weights, with scores ranging from approximately 0 (death) to 1 (full health).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Presenteeism
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
Time frame: Baseline, week 32, and week 52
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Absenteeism
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
Time frame: Baseline, week 32, and week 52
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Work Productivity Impairment
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
Time frame: Baseline, week 32, and week 52
Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Activity Impairment
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
Time frame: Baseline, week 32, and week 52
Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.
Time frame: Baseline, week 32, and week 52
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.
Time frame: Baseline, week 32, and week 52
Percentage of Participants Achieving a BASDAI 50 Response
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.
Time frame: Baseline, week 32, and week 52
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 (best) to 10 (worst).
Time frame: Baseline, week 32, and week 52
Change From Baseline in ASDAS(CRP)
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." Change from baseline in ASDAS calculated using CRP is reported.
Time frame: Baseline, week 32, and week 52
Percentage of Participants Achieving ASDAS(CRP) Major Improvement
ASDAS Major Improvement is defined as a change from baseline ≤ -2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with major improvement in ASDAS calculated using CRP is reported.
Time frame: Baseline, week 32, and week 52
Percentage of Participants Achieving ASDAS(CRP) Clinically Important Improvement
ASDAS clinically important improvement is defined as a change from baseline ≤ -1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with clinically important improvement in ASDAS calculated using CRP is reported.
Time frame: Baseline, week 32, and week 52
Percentage of Participants With ASDAS Inactive Disease at Week 52
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.
Time frame: Week 52
Percentage of Participants With ASDAS Low Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity (defined as ASDAS \< 2.1) calculated using CRP is reported.
Time frame: Week 32 and week 52
Percentage of Participants With ASDAS Moderate Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity (defined as an ASDAS ≥ 1.3 to \< 2.1) calculated using CRP is reported.
Time frame: Week 32 and week 52
Percentage of Participants With ASDAS High Disease Activity
ASDAS high disease activity is defined as an ASDAS ≥ 2.1 to \< 3.5. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with high disease activity (defined as an ASDAS ≥ 2.1 to \< 3.5) calculated using CRP is reported.
Time frame: Week 32 and week 52
Percentage of Participants With ASDAS Very High Disease Activity
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with very high disease activity (defined as an ASDAS \> 3.5) calculated using CRP is reported
Time frame: Week 32 and week 52
Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response
ASAS20 response was defined as improvement of ≥ 20% relative to baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline, week 32, and week 52
Percentage of Participants Achieving an ASAS 40 Response
ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline, week 32, and week 52
Percentage of Participants Achieving ASAS Partial Remission
ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Week 32 and week 52
Change From Baseline in Active Inflammation of the Sacroiliac Joints and Spine
Active inflammation of the sacroiliac (SI) joints as well as the cervical, thoracic and lumbar regions of the spine was assessed using magnetic resonance imaging (MRI). Images were scored by a central reader according to the Berlin MRI Score on a grading scale from 0 to 3, where Grade 0 indicates no active inflammation and Grade 3 indicates \> 66% inflammation of the sacroiliac joints or \> 50% active inflammation in the spine.
Time frame: Baseline and week 52
Change From Baseline in Physician's Global Assessment of Disease Activity
The Physician's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (severe disease activity).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Patient's Global Assessment of Disease Activity
The Patient's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (very severe disease activity).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Patient's Global Assessment of Pain
The Patient's Global Assessment of Pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Swollen Joint Count
An assessment of 66 joints was performed by physical examination of each joint. The swollen joint count is the number of joints assessed as swollen (0 to 66).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Tender Joint Count
An assessment of 68 joints was performed by physical examination of each joint. The tender joint count is the number of joints assessed as tender (0 to 68).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES)
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at 13 entheses (sites where tendons or ligaments insert into the bone). All sites were scored as 0 (absent) or 1 (present). The MASES is the sum of all site scores (from 0 to 13).
Time frame: Baseline, week 32, and week 52
Change From Baseline in Dactylitis Count
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as 0 for no dactylitis or 1 for dactylitis present. The dactylitis count, ranging from 0 to 20, is the total number of digits on the hands and feet with dactylitis present.
Time frame: Baseline, week 32, and week 52
Change From Baseline in the Erythrocyte Sedimentation Rate (ESR)
Erythrocyte sedimentation rate measures the rate of fall (sedimentation) of erythrocytes (red blood cells) in a sample of blood that has been placed into a tall, thin, vertical tube as an indirect measure of the degree of inflammation present in the body.
Time frame: Baseline, week 32, and week 52
Change From Baseline in C-reactive Protein (CRP)
CRP is an acute phase reactant is a blood test marker for inflammation in the body. CRP levels rise in response to inflammation.
Time frame: Baseline, week 32, and week 52
Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)
The linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin) is a composite score based on 5 direct measurements of spinal mobility: lateral lumbar flexion, tragus-to-wall distance, lumbar flexion, intermalleolar distance, and cervical rotation angle. The total score ranges from 0 to 10, where higher scores indicate more limited mobility.
Time frame: Baseline, week 32, and week 52
Number of Participants With New Onset Anterior Uveitis
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
Time frame: Up to Week 52
The study planned to enroll approximately 240 participants at 30 sites in Germany. Due to slow enrollment the study was terminated prematurely; at the time the decision to close the study was made 22 subjects were enrolled at 9 sites in Germany.
| Milestone | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Started | 14 | 8 |
| Completed | 3 | 0 |
| Not completed | 11 | 8 |
| Withdrew: Early termination of study by sponsor | 11 | 8 |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (C-reactive protein \[CRP\] or erythrocyte sedimentation rate \[ESR\]) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Percentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 32 | 80.0 | 0.0 |
The EQ-5D-3L is a health state utility instrument that evaluates preference for health status (utility). The 5 items in the EQ-5D-3L comprise 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which are rated on 3 levels of severity (1: indicating no problem, 2: indicating some/moderate problems, 3: indicating extreme problems). A single preference-weighted health utility index score was calculated by applying country-specific weights, with scores ranging from approximately 0 (death) to 1 (full health).
| units on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 0.446 ± 0.181 | -0.287 ± NA |
| Week 52 | 0.255 ± NA | — |
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
| percent impairment | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -23.3 ± 55.1 | 20.0 ± NA |
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
| percent impairment | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -100.0 ± NA | 25.0 ± NA |
| Week 52 | -100.0 ± NA | — |
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
| percent impairment | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -90.0 ± NA | 27.5 ± NA |
| Week 52 | -80.0 ± NA | — |
The Work Productivity and Activity Impairment (WPAI) axSpA is an axSpA specific questionnaire consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
| percent impairment | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -36.0 ± 15.2 | 30.0 ± NA |
| Week 52 | -30.0 ± NA | — |
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. The ASAS HI consists of 17 questions, each answered by the participant as agree (1) or disagree (0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, with a lower score indicating a better and a higher score indicating an inferior health status.
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -4.00 ± 2.45 | 3.00 ± NA |
| Week 52 | -3.00 ± NA | — |
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10 where lower scores indicate less disease activity.
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -3.96 ± 1.68 | 3.20 ± NA |
| Week 52 | -1.83 ± 3.18 | — |
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on a 10 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For 5 questions (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from baseline in BASDAI score.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 60.0 | 0.0 |
| Week 52 | 33.3 | — |
The Bath Ankylosing Spondylitis Functional Index (BASFI) is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities, on a numeric rating scale (NRS) ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 (best) to 10 (worst).
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -2.46 ± 2.14 | -1.50 ± NA |
| Week 52 | -1.40 ± 0.849 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." Change from baseline in ASDAS calculated using CRP is reported.
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -1.29 ± 0.833 | — |
| Week 52 | -0.654 ± 1.22 | — |
ASDAS Major Improvement is defined as a change from baseline ≤ -2.0. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with major improvement in ASDAS calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 20.0 | — |
| Week 52 | 33.3 | — |
ASDAS clinically important improvement is defined as a change from baseline ≤ -1.1. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with clinically important improvement in ASDAS calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 60.0 | — |
| Week 52 | 33.3 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS inactive disease (defined as ASDAS \< 1.3) calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Percentage of Participants With ASDAS Inactive Disease at Week 52 | 33.3 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS low disease activity (defined as ASDAS \< 2.1) calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 80.0 | 0.0 |
| Week 52 | 66.7 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with ASDAS moderate disease activity (defined as an ASDAS ≥ 1.3 to \< 2.1) calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 0.0 | 0.0 |
| Week 52 | 33.3 | — |
ASDAS high disease activity is defined as an ASDAS ≥ 2.1 to \< 3.5. ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with high disease activity (defined as an ASDAS ≥ 2.1 to \< 3.5) calculated using CRP is reported.
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 20.0 | 100.0 |
| Week 52 | 33.3 | — |
ASDAS is a composite disease activity outcome measure which combines patient reported back pain, duration of morning stiffness, patient global assessment of disease activity, patient assessment of peripheral joint pain and swelling and an acute phase reactant (CRP or ESR) as an objective measure of inflammation. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS are: \< 1.3 for "inactive disease"; ≥ 1.3 to \< 2.1 for "moderate disease activity"; ≥ 2.1 to ≤ 3.5 for "high disease activity" and \> 3.5 for "very high disease activity." The percentage of participants with very high disease activity (defined as an ASDAS \> 3.5) calculated using CRP is reported
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 0.0 | 0.0 |
| Week 52 | 0.0 | — |
ASAS20 response was defined as improvement of ≥ 20% relative to baseline and absolute improvement of ≥ 1 unit (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 unit) in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 40.0 | 0.0 |
| Week 52 | 50.0 | — |
ASAS40 response was defined as improvement of ≥ 40% relative to baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration in the potential remaining domain: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 20.0 | 0.0 |
| Week 52 | 50.0 | — |
ASAS partial remission is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's Global Assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (none) to 10 (severe); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 0.0 | 0.0 |
| Week 52 | 50.0 | — |
Active inflammation of the sacroiliac (SI) joints as well as the cervical, thoracic and lumbar regions of the spine was assessed using magnetic resonance imaging (MRI). Images were scored by a central reader according to the Berlin MRI Score on a grading scale from 0 to 3, where Grade 0 indicates no active inflammation and Grade 3 indicates \> 66% inflammation of the sacroiliac joints or \> 50% active inflammation in the spine.
No measurements were reported for this outcome.
The Physician's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (severe disease activity).
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -4.00 ± 1.41 | 1.00 ± NA |
| Week 52 | -2.00 ± 3.00 | — |
The Patient's Global Assessment of Disease Activity was assessed using an NRS from 0 (no disease activity) to 10 (very severe disease activity).
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -2.20 ± 3.90 | 4.00 ± NA |
| Week 52 | -1.00 ± 3.61 | — |
The Patient's Global Assessment of Pain was assessed on a NRS from 0 (no pain) to 10 (pain as bad as it could be).
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -1.60 ± 4.28 | 3.00 ± NA |
| Week 52 | -0.333 ± 2.08 | — |
An assessment of 66 joints was performed by physical examination of each joint. The swollen joint count is the number of joints assessed as swollen (0 to 66).
| swollen joints | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 0.0000 ± 0.0000 | 0.0000 ± NA |
| Week 52 | 0.333 ± 0.577 | — |
An assessment of 68 joints was performed by physical examination of each joint. The tender joint count is the number of joints assessed as tender (0 to 68).
| tender joints | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -3.40 ± 5.98 | 1.00 ± NA |
| Week 52 | -6.33 ± 6.66 | — |
The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at 13 entheses (sites where tendons or ligaments insert into the bone). All sites were scored as 0 (absent) or 1 (present). The MASES is the sum of all site scores (from 0 to 13).
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -0.800 ± 1.79 | 0.0000 ± NA |
| Week 52 | 0.333 ± 1.53 | — |
Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as 0 for no dactylitis or 1 for dactylitis present. The dactylitis count, ranging from 0 to 20, is the total number of digits on the hands and feet with dactylitis present.
| digits with dactylitis | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | 0.0000 ± 0.0000 | 0.0000 ± NA |
| Week 52 | 0.0000 ± 0.0000 | — |
Erythrocyte sedimentation rate measures the rate of fall (sedimentation) of erythrocytes (red blood cells) in a sample of blood that has been placed into a tall, thin, vertical tube as an indirect measure of the degree of inflammation present in the body.
| mm/hour | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -2.60 ± 3.05 | 0.0000 ± NA |
| Week 52 | -4.00 ± 3.46 | — |
CRP is an acute phase reactant is a blood test marker for inflammation in the body. CRP levels rise in response to inflammation.
| mg/L | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -4.47 ± 4.38 | -1.00 ± NA |
| Week 52 | -3.47 ± 6.00 | — |
The linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin) is a composite score based on 5 direct measurements of spinal mobility: lateral lumbar flexion, tragus-to-wall distance, lumbar flexion, intermalleolar distance, and cervical rotation angle. The total score ranges from 0 to 10, where higher scores indicate more limited mobility.
| score on a scale | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Week 32 | -1.00 ± 0.632 | -1.10 ± NA |
| Week 52 | -1.20 ± 0.944 | — |
Anterior uveitis is an inflammation of the middle layer of the eye. which includes the iris (colored part of the eye) and the adjacent tissue, known as the ciliary body.
| Participants | Treat-to-Target (T2T) | Standard of Care (SOC) |
|---|---|---|
| Number of Participants With New Onset Anterior Uveitis | 0 | 0 |
Collected over Up to 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care (SOC) | 0/8 (0%) | 0/8 (0%) | 6/8 (75%) |
| Treat-to-Target (T2T) | 0/14 (0%) | 1/14 (7.1%) | 12/14 (85.7%) |
| Event | Standard of Care (SOC) | Treat-to-Target (T2T) |
|---|---|---|
| CHOLECYSTITIS CHRONICHepatobiliary disorders | 0/8 | 1/14 |
| Event | Standard of Care (SOC) | Treat-to-Target (T2T) |
|---|---|---|
| NASOPHARYNGITISInfections and infestations | 3/8 | 4/14 |
| AXIAL SPONDYLOARTHRITISMusculoskeletal and connective tissue disorders | 3/8 | 2/14 |
| GASTROENTERITISInfections and infestations | 2/8 | 1/14 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 1/8 | 3/14 |
| GASTRITISGastrointestinal disorders | 0/8 | 2/14 |
| NAUSEAGastrointestinal disorders | 0/8 | 2/14 |
| BACK PAINMusculoskeletal and connective tissue disorders | 0/8 | 2/14 |
| HEADACHENervous system disorders | 0/8 | 2/14 |
| TOOTHACHEGastrointestinal disorders | 1/8 | 0/14 |
| CYSTITISInfections and infestations | 1/8 | 1/14 |
| Age, Continuous(years) | Treat-to-Target (T2T) | Standard of Care (SOC) | Total |
|---|---|---|---|
| Mean | 37.0 ± 9.49 | 29.6 ± 7.96 | 34.3 ± 9.49 |
| Sex: Female, Male(Participants) | Treat-to-Target (T2T) | Standard of Care (SOC) | Total |
|---|---|---|---|
| Female | 8 | 4 | 12 |
| Male | 6 | 4 | 10 |
| Race and Ethnicity Not Collected(Participants) | Treat-to-Target (T2T) | Standard of Care (SOC) | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Sep 2016 to primary completion in Dec 2017, 15 months.
Results were first posted in Jul 2019, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab